Literature DB >> 19346461

Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension.

Inês Falcão-Pires1, Nádia Gonçalves, Tiago Henriques-Coelho, Daniel Moreira-Gonçalves, Roberto Roncon-Albuquerque, Adelino F Leite-Moreira.   

Abstract

We investigated the endogenous production of apelin and the cardiac and pulmonary effects of its chronic administration in monocrotaline (MCT)-induced pulmonary hypertension (PH). Male Wistar rats were injected with MCT (60 mg/kg sc) or vehicle (day 0). One week later, these animals were randomly treated during 17 days with pyroglutamylated apelin-13 (Pyr-AP13; 200 microg*kg(-1)*day(-1) ip) or a similar volume of saline, resulting in four groups: sham (n = 11), sham-AP (n = 11), MCT (n = 16), and MCT-AP (n = 13). On day 25, right ventricular (RV) and left ventricular (LV) hemodynamic and morphometric parameters were assessed. Tissue and plasma samples were collected for histological and molecular analysis. When compared with sham, the MCT group presented a significant increase of RV mass (166 +/- 38%), diameter of cardiomyocyte (40 +/- 10%), myocardial fibrosis (95 +/- 20%), peak systolic pressure (99 +/- 22%), peak rate of ventricular pressure rise (dP/dt(max); 74 +/- 24%), peak rate of ventricular pressure decline (dP/dt(min); 73 +/- 19%), and time constant tau (55 +/- 16%). In these animals, RV expression of apelin (-73 +/- 10%) and its receptor APJ (-61 +/- 20%) was downregulated, whereas mRNA expression of type B natriuretic peptide (9,606 +/- 713%), angiotensinogen (191 +/- 147%), endothelin-1 (RV, 497 +/- 156%; and LV, 799 +/- 309%), plasmatic levels of apelin (104 +/- 48%), and angiotensin 1-7 (161 +/- 151%) were increased. Chronic treatment with Pyr-AP13 significantly attenuated or normalized these changes, preventing apelin-APJ mRNA downregulation and PH-induced neurohumoral activation of several vasoconstrictors, which exacerbates apelin-APJ vasodilator effects. Therefore, apelin delayed the progression of RV hypertrophy and diastolic dysfunction. Together, these observations suggest that the apelin-APJ system may play an important role in the pathophysiology of PH, representing a potential therapeutic target since it significantly attenuates RV overload and PH-induced neurohumoral activation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19346461     DOI: 10.1152/ajpheart.00089.2009

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  53 in total

Review 1.  Right ventricular failure: a novel era of targeted therapy.

Authors:  Dipanjan Banerjee; Francois Haddad; Roham T Zamanian; Jayan Nagendran
Journal:  Curr Heart Fail Rep       Date:  2010-12

Review 2.  The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders.

Authors:  Eric Marsault; Catherine Llorens-Cortes; Xavier Iturrioz; Hyung J Chun; Olivier Lesur; Gavin Y Oudit; Mannix Auger-Messier
Journal:  Ann N Y Acad Sci       Date:  2019-06-25       Impact factor: 5.691

3.  Apelin decreases lipolysis via G(q), G(i), and AMPK-Dependent Mechanisms.

Authors:  Patrick Yue; Hong Jin; Shiming Xu; Marissa Aillaud; Alicia C Deng; Junya Azuma; Ramendra K Kundu; Gerald M Reaven; Thomas Quertermous; Philip S Tsao
Journal:  Endocrinology       Date:  2010-11-03       Impact factor: 4.736

4.  ERG-APLNR axis controls pulmonary venule endothelial proliferation in pulmonary veno-occlusive disease.

Authors:  Christopher Lathen; Yu Zhang; Jennifer Chow; Martanday Singh; Grace Lin; Vishal Nigam; Yasser A Ashraf; Jason X Yuan; Ivan M Robbins; Patricia A Thistlethwaite
Journal:  Circulation       Date:  2014-07-25       Impact factor: 29.690

5.  Restoration of impaired endothelial myocyte enhancer factor 2 function rescues pulmonary arterial hypertension.

Authors:  Jongmin Kim; Cheol Hwangbo; Xiaoyue Hu; Yujung Kang; Irinna Papangeli; Devi Mehrotra; Hyekyung Park; Hyekyung Ju; Danielle L McLean; Suzy A Comhair; Serpil C Erzurum; Hyung J Chun
Journal:  Circulation       Date:  2014-10-21       Impact factor: 29.690

6.  Apelin attenuates hyperoxic lung and heart injury in neonatal rats.

Authors:  Yvonne P de Visser; Frans J Walther; El Houari Laghmani; Arnoud van der Laarse; Gerry T M Wagenaar
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

Review 7.  Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension.

Authors:  Andrea L Frump; Sébastien Bonnet; Vinicio A de Jesus Perez; Tim Lahm
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-11-02       Impact factor: 5.464

8.  Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension.

Authors:  Suparna M Chandra; Hedi Razavi; Jongmin Kim; Rani Agrawal; Ramendra K Kundu; Vinicio de Jesus Perez; Roham T Zamanian; Thomas Quertermous; Hyung J Chun
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-01-13       Impact factor: 8.311

Review 9.  Advances in therapeutic peptides targeting G protein-coupled receptors.

Authors:  Anthony P Davenport; Conor C G Scully; Chris de Graaf; Alastair J H Brown; Janet J Maguire
Journal:  Nat Rev Drug Discov       Date:  2020-03-19       Impact factor: 84.694

10.  Decreased apelin and apelin-receptor expression in the pulmonary vasculature of nitrofen-induced congenital diaphragmatic hernia.

Authors:  Alejandro D Hofmann; Florian Friedmacher; Hiromizu Takahashi; Manuela Hunziker; Jan-Hendrik Gosemann; Prem Puri
Journal:  Pediatr Surg Int       Date:  2014-02       Impact factor: 1.827

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.